We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Findings May Lead to Enhanced Treatments for Multiple Sclerosis and Autoimmune Inflammation

By LabMedica International staff writers
Posted on 10 Dec 2014
A multidisciplinary research team of scientists from Singapore has made a breakthrough discovery of a new type of immune cells that may help in the development of a future treatment for multiple sclerosis (MS).

Led by Prof. More...
Xin-Yuan Fu, senior lead investigator from CSI Singapore and professor at the department of biochemistry at the National University of Singapore (NUS) Yong Loo Lin School of Medicine (Singapore), and Dr. Wanqiang Sheng, postdoctoral fellow at CSI Singapore, the scientists discovered that a new type of immune T helper cells called TH-GM cells play a crucial role in the immune system and pathogenesis of neuronal inflammation. The findings offer insights into a potential new avenue for therapeutic intervention, which can be used independently or combined with other treatment options to optimize outcomes in the treatment of MS.

Working with Dr. Yong-Liang Zhang, from the department of microbiology at the NUS Yong Loo Lin School of Medicine, Prof. Fu and his team demonstrated that STAT5, a member of the STAT family of proteins, programs TH-GM and triggers the immune response to an autoantigen in responding to a signal from an interleukin, IL-7, causing neuroinflammation, pathogenesis and damage in the central nervous system. Blocking IL-7 or STAT5 would provide a substantial therapeutic benefit for this disease. The study’s findings were published online November 21, 2014, in the journal Cell Research.

MS is the most prevalent autoimmune disease of the central nervous system, affecting about 2.5 million people worldwide, with cases showing a higher prevalence in Northern Europe. In spite of many years of research, the causes of MS are mostly not known and the disease remains incurable.

This study provides vital clues into the processes behind MS. Dr. Richard Flavell, chair of the department of immunology at Yale University (New Haven, CT, USA), and a world leader in the immunology field, noted that the findings from the study may now provide a mechanistic link between IL-7/STAT5-mediated signaling and T helper cell-mediated pathogenicity.

The STAT family of proteins and their signaling pathway (called JAK-STAT) were first discovered by Prof. Fu and his colleagues in 1992. Disturbance of this pathway was shown to be a major cause for many kinds of inflammatory disorders. Innovative drugs interfering with JAK-STAT have since been approved in the United States, Europe, and Singapore for the treatment of numerous diseases, and annual sales of medicines involving JAK-STAT are expected to exceed USD 1.6 billion in 2016. The newly discovered IL-7-STAT5 by Prof. Fu and his team in neuroinflammation considerably expands this line of medical research, development, and therapeutic intervention in a variety of major diseases.

Prof. Fu and collegues are now researching the physiologic function of TH-GM to further the development of therapy for various human autoimmune diseases.

Related Links:

CSI Singapore
National University of Singapore Yong Loo Lin School of Medicine



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.